X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AVE-901 (tramadol) inhibits serotonin reuptake and norepinephrine reuptake, enhancing inhibitory effects on pain transmission in the spinal cord. It is being developed for the treatment of post-operative pain.
Lead Product(s): Tramadol Hydrochloride
Therapeutic Area: Neurology Product Name: AVE-901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
AJ201 is an oral Nrf1/Nrf2 stimulator which is under phase 1/2 clinical development for the treatment of patients with Spinal and Bulbar Muscular Atrophy (Kennedy's Disease).
Lead Product(s): AJ201
Therapeutic Area: Musculoskeletal Product Name: AJ201
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
The net proceeds will be used for the development AJ201 (JM17), a first-in-class oral small molecule for spinal and bulbar muscular atrophy, , a neurodegenerative disease associated with abnormal aggregation of the androgen receptor protein with a polyQ stretch.
Lead Product(s): JM17
Therapeutic Area: Neurology Product Name: AJ201
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Maxim Group LLC
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 02, 2023
Details:
The net proceeds will be used for the development AJ201 (JM17), a first-in-class oral small molecule for spinal and bulbar muscular atrophy, , a neurodegenerative disease associated with abnormal aggregation of the androgen receptor protein with a polyQ stretch.
Lead Product(s): JM17
Therapeutic Area: Neurology Product Name: AJ201
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Maxim Group LLC
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 31, 2023
Details:
BAER-101, the Company’s potentially best-in-class selective GABA-A α2,3 positive allosteric modulator (“PAM”), significantly suppressed seizures in a translational animal model of absence epilepsy.
Lead Product(s): BAER-101
Therapeutic Area: Neurology Product Name: BAER-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
AJ201 is a novel first-in-class asset in development for the treatment of spinal and bulbar muscular atrophy. It was designed to modify SBMA through multiple mechanism including degradation of the abnormal androgen receptor protein and by stimulating the Nrf1 and Nrf2 pathway.
Lead Product(s): AJ201
Therapeutic Area: Musculoskeletal Product Name: AJ201
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AnnJi Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
AVE-901 (tramadol) inhibits serotonin reuptake and norepinephrine reuptake, enhancing inhibitory effects on pain transmission in the spinal cord. It is being developed for the treatment of post-operative pain.
Lead Product(s): Tramadol Hydrochloride
Therapeutic Area: Neurology Product Name: AVE-901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
AVE-901 (tramadol) inhibits serotonin reuptake and norepinephrine reuptake, enhancing inhibitory effects on pain transmission in the spinal cord. It is being developed for the treatment of post-operative pain.
Lead Product(s): Tramadol Hydrochloride
Therapeutic Area: Neurology Product Name: AVE-901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
Under the terms of the license agreement, avenue therapeutics will develop and commercialize AJ201, a first-in-class clinical asset for the treatment of kennedy's disease. AnnJi will retain the manufacturing right to provide clinical and commercial supply of AJ201 to avenue.
Lead Product(s): AJ201
Therapeutic Area: Musculoskeletal Product Name: AJ201
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: AnnJi Pharmaceutical
Deal Size: $253.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement March 10, 2023
Details:
Under the agreement, Avenue Therapeutics will Develop and Commercialize AJ201, a first-in-class clinical asset currently in a Phase 1b/2a study in the U.S. for the treatment of spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's Disease.
Lead Product(s): AJ201
Therapeutic Area: Musculoskeletal Product Name: AJ201
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: AnnJi Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $3.0 million
Deal Type: Licensing Agreement March 02, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
